NAFAMOSTAT MESILATE - A REGIONAL ANTICOAGULANT FOR HEMODIALYSIS IN PATIENTS AT HIGH-RISK FOR BLEEDING
NAFAMOSTAT MESILATE - A REGIONAL ANTICOAGULANT FOR HEMODIALYSIS IN PATIENTS AT HIGH-RISK FOR BLEEDING
复制标题
DOI：
10.1159/000187357
复制
发表时间：
1993-07-01
期刊：
影响因子：
2.5
通讯作者：
HIRASAWA, Y
中科院分区：
文献类型：
--
作者：
AKIZAWA, T;KOSHIKAWA, S;HIRASAWA, Y
107例因既往手术或其他部位活动性出血而存在透析中出血高风险的血液透析患者接受甲磺酸萘莫司他（FUT-175; FUT）作为血液透析抗凝剂治疗2周。与肝素不同。FUT仅在体外回路中延长凝血时间。即使在治疗结束时，凝血时间也没有延长，拔出针头后穿刺部位出血的时间也短于肝素。在573例血液透析手术中仅21例（3.7%）观察到血液透析出血加重，145例活动性出血的血液透析手术中有134例（92.4%）成功完成，未增加出血。仅在6例（5.6%）或1.2%的HD手术中观察到FUT的不良反应。这些结果表明，FUT是一个非常有用的抗凝血的血液透析，特别是在高出血风险的患者。
107 hemodialysis patients at high risk for intradialytic bleeding due to previous surgery or active bleeding from other sites were treated with nafamostat mesilate (FUT-175; FUT) as hemodialysis anticoagulant for 2 weeks. In contrast to heparin. FUT prolonged clotting times only in the extracorporeal circuit. Clotting times were not prolonged even at the conclusion of the treatment, and bleeding from the puncture site after removal of the needle was shorter than with heparin. The exacerbation of bleeding by hemodialysis was noted in only 21 out of 573 hemodialysis procedures (3.7%), and 134 of 145 hemodialysis procedures (92.4%) with active bleeding were successfully completed without increasing the bleeding. Adverse effects of FUT were noted in only 6 cases (5.6%) or 1.2% of HD procedures. These results indicate that FUT is a very useful anticoagulant for HD, especially in patients with high risk of bleeding.